Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
US Army
McKinsey
Queensland Health
Dow
Accenture
Baxter
Teva
Novartis
Farmers Insurance

Generated: February 20, 2018

DrugPatentWatch Database Preview

HEMANGEOL Drug Profile

« Back to Dashboard

Which patents cover Hemangeol, and what generic alternatives are available?

Hemangeol is a drug marketed by Pierre Fabre Derma and is included in one NDA. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty countries.

The generic ingredient in HEMANGEOL is propranolol hydrochloride. There are twenty-one drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.
Summary for HEMANGEOL
Drug patent expirations by year for HEMANGEOL
Pharmacology for HEMANGEOL
Medical Subject Heading (MeSH) Categories for HEMANGEOL

US Patents and Regulatory Information for HEMANGEOL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pierre Fabre Derma HEMANGEOL propranolol hydrochloride SOLUTION;ORAL 205410-001 Mar 14, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for HEMANGEOL

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,987,262 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ➤ Try a Free Trial
9,173,858 Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for HEMANGEOL

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Dow
Teva
Merck
UBS
Fish and Richardson
Medtronic
Federal Trade Commission
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot